{
  "docId": "019de076-5923-773b-8485-b914b8e85d5b",
  "docSlug": "aa767e092bc23262b7b522a6b0c001e5",
  "documentTitle": "MindMed | Results Presentation Deck | 20 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 20,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide illustrates six different candidate dose-response curves used in the MCP-Mod statistical framework.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5923-773b-8485-b914b8e85d5b/14",
  "deckHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b",
  "deckJsonHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b.json",
  "deckAnchorHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.45,
        "x": 0.51,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Candidate dose-response curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e1f2b17-e6a7-4925-8d91-439053110719",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "framework",
      "text": "Multiple Comparison Procedure Modelling (MCP-Mod)",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "937d9d33-307d-4bd9-b31b-2fbb9d56c008",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Qualification opinions from both FDA and EMA: FDA: \"MCP-Mod method is found more effective than pairwise comparison due to its ability to utilize all available data\". EMA: \"The MCP-Mod approach is efficient in the sense that it uses the available data better than the commonly applied pairwise comparisons...\"",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bbb3690-81a3-4648-8a20-bf729059c00b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Statistical methodology for dose-response developed by Novartis in 2004. Involves establishing a dose-response signal using multiple comparison procedures and then estimating the dose-response curve and target doses of interest using modelling techniques.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55889a5a-18ce-4f02-ac91-d191659e02a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Novartis. \"The MCP-Mod methodology - A statistical methodology for dose-response. 2. FDA, Office of Clinical Pharmacology, Division of Pharmacometrics. 3. EMA, Committee for Medicinal Products for Human Use",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83caf879-922f-48a8-867a-a7cd528d7efb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) - Primary Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71778449-9d49-49c3-98d5-31d65963b214",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "analytical-method",
      "slug": null,
      "matchId": "aa70f9bb-90fb-4ce6-aad1-4826ebde0393",
      "evidence": "MCP-Mod statistical methodology description",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "43b0daed-c25d-4529-ba07-29b26d748e8f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 8-14 provide evidence and proof of concept for MindMed's product candidates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}